Bajaj Finserv Healthcare Fund
- NAV as on 9 Nov 2026
- ₹12.19+2.93%1 day
- Return since launch
- 9.1%
- 52-week range
- ₹8.97 — ₹12.08
- AUM
- ₹405 Cr
Bajaj Finserv Healthcare Fund is a Sectoral-Pharma equity fund from Bajaj Finserv Mutual Fund with ₹405 Cr under management, launched in 2024. The expense ratio is 2.59% and the SEBI riskometer reading is Very High.
Performance
Bajaj Finserv Healthcare Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +24.6% against +19.9% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 36.8% | +16.0 pts | 20.8% | 29.1% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 8.8% | +0.3 pts | 8.4% | 8.5% |
| 3M | 4.5% | +0.8 pts | 3.7% | 3.7% |
| 6M | 17.6% | +3.6 pts | 14.0% | 13.6% |
| 1Y | 23.8% | +3.0 pts | 20.8% | 19.4% |
Since launch (6 Dec 2024): 9.1%
Calendar-year returns
Category averageShow as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -4.6% | −2.5 pts | -2.0% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.59%
Expense ratio as on 6 Nov 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 2.09%
- Brokerage
- 0.04%
- Transaction charges
- 0.00%
- Statutory levies
- 0.46%
- Exit load
- 1% for redemption within 3 Months
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
Bajaj Finserv Healthcare Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity95.6%
- Debt3.7%
- Other0.8%
Market cap split
- Large31.7%
- Mid30.1%
- Small38.1%
- P/E
- 48.10
- P/B
- 5.99
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Divi's Laboratories Ltd. | Healthcare | 9.75% | ₹39.52 Cr | +8.40% | +8.95% | +7.75% |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 8.96% | ₹36.30 Cr | +6.36% | +9.41% | +7.53% |
| Piramal Pharma Ltd. | Healthcare | 6.36% | ₹25.75 Cr | +6.04% | +5.69% | +3.23% |
| Rubicon Research Ltd. | Healthcare | 6.08% | ₹24.61 Cr | +6.02% | +3.84% | — |
| Aurobindo Pharma Ltd. | Healthcare | 6.03% | ₹24.43 Cr | +6.52% | +6.63% | +3.44% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.51% | ₹22.34 Cr | +6.71% | +6.75% | +6.29% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 4.78% | ₹19.36 Cr | +5.26% | +5.57% | +1.42% |
| Emcure Pharmaceuticals Ltd. | Healthcare | 4.03% | ₹16.33 Cr | +4.36% | +4.35% | +3.26% |
| Laurus Labs Ltd. | Healthcare | 3.91% | ₹15.84 Cr | +2.14% | +1.65% | — |
| Neuland Laboratories Ltd. | Healthcare | 3.82% | ₹15.46 Cr | +4.59% | +3.42% | +3.78% |
| Others | Others | 3.13% | ₹12.71 Cr | +2.82% | +0.04% | +5.94% |
| Max Healthcare Institute Ltd. | Healthcare | 2.99% | ₹12.12 Cr | +4.16% | +4.06% | +1.21% |
| Alkem Laboratories Ltd. | Healthcare | 2.96% | ₹12.00 Cr | — | — | +1.61% |
| Zydus Lifesciences Ltd. | Healthcare | 2.57% | ₹10.41 Cr | +1.40% | — | — |
| Ipca Laboratories Ltd. | Healthcare | 2.40% | ₹9.73 Cr | +2.43% | +2.69% | +2.10% |
| Fortis Healthcare Ltd. | Healthcare | 2.28% | ₹9.25 Cr | +3.25% | +3.18% | +3.83% |
| Zydus Wellness Ltd. | Consumer Staples | 2.20% | ₹8.90 Cr | +2.82% | +2.46% | +1.96% |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 2.19% | ₹8.87 Cr | +2.36% | +1.77% | +1.91% |
| Senores Pharmaceuticals Ltd. | Healthcare | 2.08% | ₹8.45 Cr | +2.29% | — | — |
| Shaily Engineering Plastics Ltd. | Materials | 1.88% | ₹7.60 Cr | +2.03% | +1.72% | +1.68% |
| Dr. Lal Pathlabs Ltd. | Healthcare | 1.73% | ₹7.00 Cr | +1.64% | +1.54% | +3.24% |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 1.63% | ₹6.59 Cr | +1.65% | +1.81% | +1.73% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 1.60% | ₹6.48 Cr | +1.73% | +1.97% | +2.97% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 1.37% | ₹5.55 Cr | — | — | +3.43% |
| Cipla Ltd. | Healthcare | 1.33% | ₹5.38 Cr | — | — | +5.45% |
| Bajaj Finserv Money Market Fund Direct-Growth | Unclassified | 1.31% | ₹5.31 Cr | +1.48% | +1.71% | — |
| Sanofi Consumer Healthcare India Ltd. | Healthcare | 1.30% | ₹5.27 Cr | +1.80% | +1.98% | +2.03% |
| Biocon Ltd. | Healthcare | 1.05% | ₹4.24 Cr | +1.35% | +1.38% | +3.59% |
| Navin Fluorine International Ltd. | Chemicals | 0.94% | ₹3.80 Cr | +2.17% | +2.05% | — |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 0.92% | ₹3.73 Cr | +1.15% | +1.03% | — |
| Jubilant Pharmova Ltd. | Healthcare | 0.89% | ₹3.60 Cr | +0.96% | +0.95% | +1.17% |
| Onesource Specialty Pharma Ltd. | Healthcare | 0.83% | ₹3.35 Cr | — | — | — |
| Medi Assist Healthcare Services Ltd. | Services | 0.75% | ₹3.04 Cr | +1.04% | +0.99% | +1.63% |
| Neogen Chemicals Ltd. | Chemicals | 0.23% | ₹0.94 Cr | — | — | +0.44% |
| Sumitomo Chemical India Ltd. | Chemicals | 0.21% | ₹0.87 Cr | — | — | — |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Alkem Laboratories Ltd. | 0.00% | 2.96% | +2.96% |
| Laurus Labs Ltd. | 2.36% | 3.91% | +1.55% |
| Turtlemint Fintech Solutions Ltd. | 0.92% | 0.00% | -0.92% |
| Divi's Laboratories Ltd. | 10.55% | 9.75% | -0.80% |
| Sun Pharmaceutical Industries Ltd. | 8.21% | 8.96% | +0.75% |
| Rubicon Research Ltd. | 6.81% | 6.08% | -0.73% |
| Apollo Hospitals Enterprise Ltd. | 6.00% | 5.51% | -0.49% |
| Fortis Healthcare Ltd. | 2.69% | 2.28% | -0.41% |
| Max Healthcare Institute Ltd. | 3.35% | 2.99% | -0.36% |
| Piramal Pharma Ltd. | 6.72% | 6.36% | -0.36% |
| Neuland Laboratories Ltd. | 4.11% | 3.82% | -0.29% |
| MTAR Technologies Ltd. | 0.26% | 0.00% | -0.26% |
| Torrent Pharmaceuticals Ltd. | 5.03% | 4.78% | -0.25% |
| Others | 2.12% | 2.32% | +0.20% |
| Emcure Pharmaceuticals Ltd. | 3.84% | 4.03% | +0.19% |
| Glaxosmithkline Pharmaceuticals Ltd. | 1.79% | 1.63% | -0.16% |
| Aurobindo Pharma Ltd. | 6.18% | 6.03% | -0.15% |
| Jubilant Pharmova Ltd. | 0.76% | 0.89% | +0.13% |
| Shaily Engineering Plastics Ltd. | 2.00% | 1.88% | -0.12% |
| Vijaya Diagnostic Centre Ltd. | 2.31% | 2.19% | -0.12% |
| Biocon Ltd. | 1.16% | 1.05% | -0.11% |
| Sanofi Consumer Healthcare India Ltd. | 1.41% | 1.30% | -0.11% |
| Glenmark Pharmaceuticals Ltd. | 1.70% | 1.60% | -0.10% |
| Dr. Reddy's Laboratories Ltd. | 1.28% | 1.37% | +0.09% |
| Medi Assist Healthcare Services Ltd. | 0.82% | 0.75% | -0.07% |
| Senores Pharmaceuticals Ltd. | 2.15% | 2.08% | -0.07% |
| Zydus Wellness Ltd. | 2.27% | 2.20% | -0.07% |
| Ipca Laboratories Ltd. | 2.46% | 2.40% | -0.06% |
| Cipla Ltd. | 1.39% | 1.33% | -0.06% |
| Dr. Lal Pathlabs Ltd. | 1.68% | 1.73% | +0.05% |
| Navin Fluorine International Ltd. | 0.99% | 0.94% | -0.05% |
| Sumitomo Chemical India Ltd. | 0.25% | 0.21% | -0.04% |
| Neogen Chemicals Ltd. | 0.21% | 0.23% | +0.02% |
| Bajaj Finserv Money Market Fund Direct-Growth | 1.30% | 1.31% | +0.01% |
| Krishna Institute of Medical Sciences Ltd | 0.93% | 0.92% | -0.01% |
| Onesource Specialty Pharma Ltd. | 0.82% | 0.83% | +0.01% |
| Zydus Lifesciences Ltd. | 2.56% | 2.57% | +0.01% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,934 Cr | 1.89% | 36.5% | 20.8% | 21.6% |
 SBI Healthcare Opportunities Fund | ₹6,067 Cr | 1.98% | 35.0% | 19.9% | 22.6% |
 HDFC Pharma And Healthcare Fund | ₹3,501 Cr | 2.11% | 39.6% | 25.8% | — |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 37.3% | 20.2% | 21.1% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 30.6% | 18.4% | 21.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹177 Cr | 1.13% | 39.9% | 19.9% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
Fund managers
- Siddharth ChaudharyMr. Chaudhary is a B.Com (H) and PGDM (Securities Markets).Prior to joining Bajaj Finserv Mutual Fund, he has worked with Sundaram Mutual Fund and Indian Bank.
- Sorbh GuptaMr. Gupta is a B.Com, CA and CFA.Prior to joining Bajaj Finserv Mutual Fund, he was associated with Quantum Mutual Fund, Siddhesh Capital Markets Pvt. Ltd. & Pranav Securities Pvt. Ltd. He has over 11 years of overall experience in the equity research.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months17.56% absolute | ₹60,000 | ₹70,536 | 17.56% | |
| 1 year23.79% annualised | ₹1,20,000 | ₹1,36,645 | 13.87% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.